Summary of USP* 797 Pharmaceutical Compounding Sterile Preparations

Similar documents
USP CHAPTER <797> INTRODUCTION RISK LEVELS

2008 USPC Official 5/1/08-7/31/08 General Chapters: <797> PHARMACEUTICAL... Page 1 of PHARMACEUTICAL COMPOUNDING STERILE PREPARATIONS

Pharmacy Quality Assurance Commission Sterile Compounding [USP <797>] Self-Assessment Compliance Checklist

Guidelines for Design of. Compounded Sterile Products (CSPs) Facility

Microbiological Consideration for Non-Sterile Pharmaceutical

Facility Design for Pharmacy Operation. Full-Scale Nuclear. Slides are not to be reproduced without permission of author.

BRIEFING 797 PHARMACEUTICAL COMPOUNDING STERILE PREPARATIONS INTRODUCTION

USP <797> Compliance Common Challenges and Potential Solutions

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

HardyVal TM CSP MEDIUM-RISK LEVEL MEDIA-FILL CHALLENGE KITS

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

Pharmacy Compounding: Infection Prevention

á797ñ PHARMACEUTICAL COMPOUNDING STERILE PREPARATIONS

PHCT 401 Aseptic Processes & Techniques

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Review Validation of aseptic processes for pharmaceuticals

US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs)

Compounding Questions and Answers

USP <797> and Environmental Sampling

Chapter WAC Compounding Practices Crosswalk

FDA s Guidance for Industry

Compounding Pharmacies and Water

Learning Objectives. What is a Compounding Pharmacist? Disclosure

CGMP Requirements for Investigational Products

Thanks and acknowledgement to Pamela Isaacs for the content and slides in this presentation.

Full Contact Details:

LUNCH AND LEARN. October 14, CE Activity Information & Accreditation

Environmental Monitoring of Aseptic Processing Areas - 1

Best Practices for High Level Disinfection Part I

Latest USP Initiatives: Monographs, General Chapters, and Compounding

for IND and RDRC Regulated PET Compounding

Animal Facility Biosafety Level 3 Checklist (date: April 16, 1998)

Overview of a sterility assurance program for PET drugs

USP 797 & 800 Pharmacy Overview. (Presented to Vermont Chapter of New England Healthcare Engineers May 2016)

History and Update of Chapters 797 and 800

Aseptic Process Validation

FLORIDA SOCIETY OF HEALTH SYSTEM PHARMACISTS NOVEMBER 4, 2016 JAMES T WAGNER CONTROLLED ENVIRONMENT CONSULTING

Media Fill A Process Simution. Presented By Shikha Chauhan

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS

Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education

Completing. By the end of this chapter, you will be able to: Introduction. Chapter 16

OPERATION INTRODUCTION

HAZARDOUS MATERIALS 7/7/2016 OR THE RIGHT-TO-KNOW HAZARD COMMUNICATION STANDARD (HCS) DISCLAIMER

September 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

2-2 Sterile Product Assessment. Satish Mallya Ph.D Training Workshop CPH, May 2015

Why change is inevitable in aseptic manufacturing?

Extractables and leachables: An Introduction

Hospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco

Whitepaper. High temperature HEPA filtration. Dr.-Ing. Marc Schmidt, Dr.-Ing. Lothar Gail, Hugo Hemel MSc. Preview

Guide for Cleaning, Sterilization and Storage of Introducers for Caldera Medical Implants

MINIMUM REQUIREMENTS FOR A VENDOR

SFHPHARM18 - SQA Unit Code FA2L 04 Prepare aseptic products

Inspection Form. DPP Information. Inspection Information. Staff Information. Service Information. DPP Designated Member. Street City Postal Code

USP<797> AND THE ASEPTIC PROCESSING OF RADIOPHARMACEUTICALS PART 1

Important Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey

ASEAN Guidelines on GMP for Traditional Medicines / Health Supplement

Inspection Checklist for NIH BL3 Laboratories (7 CFR 331; 9 CFR 121; 42 CFR 73; NIH Guidelines)

Automated compounding for intravenous chemotherapy

Reference Standards for Monoclonal Antibodies: Key Challenges Addressed

Meeting of the Minds: Pharmacy Services and Integration

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE:

HardyVal TM CSP RANDOM TEST KIT

795 PHARMACEUTICAL COMPOUNDING NONSTERILE PREPARATIONS

Chuck Reed at Weiler Engineering, Inc compares aseptic blow-fill-seal technology with traditional aseptic processing of pharmaceutical liquids

Current Topics For Sterile Generic Drug Products

BRIEFING 1168 Compounding for Phase I Investigational Studies,

HISTORY AND MILESTONES

Residue removal in Cleanroom Environments

Barcodes on Unit of Use

Latest Developments in USP Monographs and the Compounding of Sterile Radiopharmaceuticals. Jim Ponto, MS, RPh, BCNP

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Validation Study on How to Avoid Microbial Contamination during Pharmaceutical Production

SPECIFICATION FOR THE DEVELOPMENT OF LPA CLEAN ROOM INFRASTRUCTURE Description of work

The GAP Analysis for Nonsterile Compounding

Analytical and formulation attributes

Annex 1 to the Good manufacturing practices guide Manufacture of sterile drugs GUI-0119

CCDEH RETAIL FOOD SAMPLING GUIDELINES

Architectural Details. Walls. Including PVC cove, UL Listed Raceway, & Integration to Flooring. AES Pharma Wall & Walk-On Ceiling Cleanroom System

Profiles in CSP Insourcing: Scripps Health

Annex A2. Guidance on Process Validation Scheme for Aseptically Processed Products

USP <800> A practical approach to compliance. Ryan W. Naseman, PharmD, MS, BCPS Michael Storey, PharmD, MS, BCPS

Visible Particles: Regulatory and Compendial Requirements

Quality is Our Promise.

MICROBIOLOGICAL BEST LABORATORY PRACTICES USP <1117>

Testosterone 20 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 ml] Tablets) Ingredient Listing Qty. Unit NDC # Supplier

The Device Side of Combination Products

UNIVERSITY OF TOLEDO HEALTH SCIENCE CAMPUS

Policies Concerning Survival Surgery of Mice

NO 2 Gas Sterilization and Decontamination: Keeping Pace, from Start to Finish

Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees

Study Summary. Results: All tested media-filled vials were negative for growth of any microorganisms.

Compounding Solutions. An advanced system for multi-ingredient solution compounding

Leachable and Extractable Testing

ABOUT HAMELN PHARMA About us

Presented to the IAPMO Standards Review Committee on January 9, 2017

Requirements of validation of packaging systems and sterility assurance

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4

Isolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite

Pharmaceutical Waste Compliance Program Clinician Educators and Managers In-Service

Transcription:

Summary of USP* 797 Pharmaceutical Compounding Sterile Preparations Source of base information Pharmacopeial Form Vol 29 (4) July Aug. 2003 Effective date January 1, 2004 FDA enforceable Scope The content of this chapter applies to health care institutions, pharmacies, physicians practice facilities and other facilities in which compounded sterile preparations are prepared, stored and dispensed. Facilities Impacted by USP 797 1. Facilities in which sterile products are prepared according to the manufacturers labeling and where manipulations are performed during the compounding of sterile products which increase the potential for microbial of the end product. 2. Facilities where products are compounded using devices or ingredients which are not sterile to prepare products which must be sterilized prior to use. 3. Products may be biologics, diagnostics, drugs, nutrients or radiopharmaceuticals which include, but are not limited to, baths and soaks for live organs and tissues, implants, inhalations, injections, irrigations, metered sprays, ophthalmic and otic preparations. Microbial Contamination Risk levels Low Risk Conditions Compounding with aseptic manipulations entirely with ISO Class 5 or better air quality using only sterile ingredients, products, components and devices Examples A. Using sterile needles and syringes to transfer sterile drugs from the manufacturer s original packaging (vials, ampoules) B. Manually measuring and mixing no more than three sterile products to compound drug admixtures and nutritional solutions. Medium Risk Conditions Multiple individual or small doses of sterile products are compounded or pooled to prepare a compounded sterile product that will be administrated either to multiple patients or to one patient on multiple occasions. The compounding process includes complex aseptic manipulations other than the single volume transfer.

Page 2 The compounding process requires an unusually long duration, such as that required to complete dissolution or homogeneous mixing. The compounded sterile products do not contain broad spectrum bacteriostatic substances and they are administered over several days For a medium risk preparation in the absence of passing a sterility test, the storage period cannot exceed the following time periods; 30 hours at room temperature, 7 days at cold temperature and 45 days in a solid frozen state at 20 C or colder. Examples A. TPN fluids compounded using manual or automated devices requiring multiple injections, detachments and attachments of the nutrient source products to the device or machine to deliver all nutritional components to the final sterile container. B. Filling of reservoirs of injection and infusion devices with multiple sterile drug products and evacuations of air from these reservoirs before the filled device is dispensed. C. Filling of reservoirs of injection and infusion devices with volumes of sterile drug solutions that will be administered over several days at ambient temperatures between 25 and 40 degrees. D. Transfer of multiple ampoules or vials into a single final sterile container or product. High Non-sterile ingredients including manufacturered products for routes of administration other than those listed under c in the introduction are incorporated or a non-sterile device is employed before terminal sterilization. Sterile ingredients, components, devices and mixtures are exposed to air quality inferior to ISO Class 5. This includes storage in environments inferior to ISO Class 5 of opened or partially used packages of manufactured sterile products that lack antimicrobial preservatives Non-sterile products are exposed to air quality inferior to ISO Class 5 for at least 6 hours before before sterilization For high risk preparations in the absence of passing a sterility test the storage periods cannot exceed the following; 24 hours at controlled room conditions, 3 days at cold temperatures and 45 days for solid frozen state at 20 C or colder.

Page 3 Examples- A. Dissolving non-sterile bulk drug and nutrient powders to make solution, which will be terminally sterilized. B. Sterile ingredients, components, devices and mixtures are exposed to air quality inferior to ISO Class 5. This includes storage in environment inferior to ISO Class 5 of opened or partially used packages of manufactured sterile products that lack antimicrobial preservatives C. Measuring and mixing sterile ingredients in non-sterile devices before sterilization is preformed. Personnel Training and Evaluation in Aseptic Manipulations Skills Personnel who prepare compounded sterile products must be provided with appropriate training from expert personnel, audio-video instructional sources, or professional sources before beginning to prepare products. Personnel shall perform didactic review, written testing, media fill testing of aseptic manipulative shills initially and at least annually for low and medium risk levels and semi annually for high risk level compounding. Media fill challenge testing will be used to access the quality of aseptic skills. Clean Rooms Low and medium risk Must have an ante area but need not be separated with a physical wall. Air classification or quality must meet ISO class 8 standards Class 100,000 Positive pressure to adjacent areas per ISO 14644-4 Physical characteristics of construction: Walls, floors, fixtures and ceilings should be smooth, impervious and free of cracks, crevices and non-shedding. Surfaces should be resistant to damage from sanitizing agents. Junctures of ceilings to walls should be coved and caulked.

Page 4 High risk Gowning If ceilings consist of inlaid panels, the panels should be impregnated with a polymer to render them impervious and hydrophobic and they should be caulked around each perimeter to seal them to the support frame. Walls may be panels locked together and sealed or epoxy coated gypsum board. Floors should be overlaid with wide sheet vinyl flooring with heat-sealed seams and coving at the sidewall. The buffer or ante area should contain no sinks or floor drains. Before entering the ante or buffer area personnel should remove outer lab coats, make-up, jewelry and thoroughly scrub hands and arms to the elbow. After drying hands and arms they should don clean non-shedding uniforms consisting of: Hair covers Shoe covers Coveralls or knee length coats ( coats to fit snugly at the wrists and be zipped or snapped in the front) Appropriate gloves Facemasks should be put on after entering the clean room Leaving and reentry Upon leaving the clean room the coveralls or coat should be carefully removed and hung outside the entry in the buffer area. Coveralls and coats can only be using for one shift. All other coverings are to be discarded and new ones donned prior to reentry. Reentry follows original gowning procedure. All of low to medium risk procedures and facilities except the ante area must be a separate room

Page 5 Barrier Isolator (MIC) A well-designed barrier isolator is an alternative to an ISO class 5 (class 100) LAFW device in an ISO class 8 clean room. The barrier isolator should be supported by adequate procedures for operation, maintenance, monitoring and control. Physical facility It is not necessary to locate the barrier isolator in a ISO class 8 area. Gowning Hair covers Shoe covers Lab coats Facemasks ( for covering facial hair) Quality Assurance Program Must have a formal audit program Formalized in writing Validation Minimum Requirements Low to Medium Risk Consider all aspects of preparation and dispensing Description of specific monitoring and evaluation activities Specifications on how results are to be reported and evaluated Identifications of appropriate follow-up mechanisms when action limits or thresholds are exceeded Delineation of the individual responsible for each aspect of the QA program. Personnel validation Three consecutive media fill runs without Revalidation - One media fill run quarterly without

Page 6 High Risk Failure of revalidation Three consecutive media fill runs without Personnel validation Three consecutive media fill runs without Revalidation - One media fill run quarterly without Failure of revalidation Three consecutive media fill runs without Process validation Three consecutive media fill runs without Revalidation - One media fill run annually without Failure of revalidation Three consecutive media fill runs without Cleaning and sanitizing the workspaces Written procedures At the beginning of each shift Environmental Monitoring Verification of sterile compounding equipment Written plan and schedule for monitoring airborne organisms Verification of particulate Verification of viable microorganisms Verification of automated compounding devices for nutrition compounding Sterility testing All high risk compounded sterile products Administered by injection into vascular and central nervous systems that are prepared in groups of 25 identical or single dose packages or in multi-dose vials for administration in multiple patients.